Floatz logo

SAFIMALTIB

Myelodysplastic Syndromes

Janssen Research & Development, LLCSmall moleculePhase 1Active
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
65/ 100

Competitive context

314 Active assets in the Myelodysplastic Syndromes cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 4BB
Anti-Thymoglobulin, Rabbit
Peking University First Hospital
Phase 2/3BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

SAFIMALTIB is also rated in:

non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →